Post-Conference Perspectives: Balstilimab In The Treatment of Cervical Cancer

EP. 1: An Overview of the Cervical Cancer Landscape: Key Advances and Recent Approvals

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, reviews the treatment landscape of cervical cancer and identifies recent approvals that have improved patient care.

EP. 2: Balstilimab in Advanced Cervical Cancer: Rationale and Key Efficacy Outcomes

November 30th 2021

Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.

EP. 3: Combining Balstilimab With Zalifrelimab in Patients With Advanced Cervical Cancer

November 30th 2021

Expert insight on the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-4 inhibitor, in patients with recurrent or metastatic cervical cancer.

EP. 4: Advanced Cervical Cancer: Toxicity Management With Balstilimab + Zalifrelimab

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, shares practical advice on managing toxicities while treating cervical cancer with the combination of balstilimab and zalifrelimab.

EP. 5: Practical Advice on Sequencing Therapies and the Care of Cervical Cancer Patients

November 30th 2021

Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.